CHELSEA THERAPEUTICS Aktie

1,48 EUR 5,1064%

Zu Ihrem Onlinebroker

kaufen verkaufen

CHELSEA THERAPEUTICS Aktienkurs : 25.05. ( 15 Min. verzögert)
1,48 € Letzter Kurs	5,11% Veränderung	1,41 € Vortag	1,48 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
1,49 - 1,48 Tag	3,05 - 1,35 52 Wochen	0 Tag	634 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

CHELSEA THERAPEUTICS Aktienku…

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

22.05.

Chelsea Therapeutics sees possible Northera delay

AP CHARLOTTE, NC (AP) — Chelsea Therapeutics International Ltd. said Tuesday it may have to make changes to a clinical trial of its drug candidate Northera, potentially...
22.05.

Chelsea Therapeutics Completes End-of-Review Meeting With FDA for Northera(TM ...

CHARLOTTE, NC, May 22, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (NASDAQ:CHTP) completed an End-of-Review meeting with the US Food and Drug Administration's (FDA) for its Northera(TM) (droxidopa) Capsules...

21.05.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) Investor files Lawsuit ...

An investor in NASDAQ:CHTP shares filed a lawsuit against directors of Chelsea Therapeutics International Ltd. over alleged breaches of fiduciary duties over certain statements made in connection with Chelsea Therapeutics' new drug Northera.
11.05.

5 Biotech Stocks At Rock Bottom Price With Takeover Possibility

Chelsea Therapeutics International Ltd (CHTP): Chelsea Therapeutics is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety...
05.05.

Chelsea eyes narrower target for Northera (Best of Weekend Rounds)

CHTP might seek limited Northera approval, meets with FDA this month Chelsea Therapeutics (NASDAQ: CHTP) won't meet with regulators until later this month to discuss its orphan drug Northera but the company is...